Clinical trials: Recurrent Non-Hodgkin Lymphoma
Lymphoma, Non-Hodgkin, Hodgkin Disease
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma…
- Trial name
- RELATIVITY-069 (NCT05255601)
- Testing
- Relatlimab, Nivolumab
- Where
- 51 sites in United States, Australia and 5 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma, Non-Hodgkin
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
- Trial name
- TRANSCENDWORLD (NCT03484702)
- Testing
- JCAR017
- Where
- 20 sites in Austria, Belgium and 9 more
- Volunteers
- 113 people
- Sponsor
- Celgene
Non Hodgkin's Lymphoma Refractory/Relapsed
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma.
- Trial name
- NCT05618925
- Testing
- N803, CD19t-haNK suspension, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
B-cell Malignancies
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
- Trial name
- TITANium (NCT06542250)
- Testing
- AZD5492
- Where
- 31 sites in United States, Australia and 8 more
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Mantle Cell Lymphoma (MCL)
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
This is an open-label, single arm, multi-center Phase 2 study of oral Rocbrutinib in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.
- Trial name
- NCT05716087
- Testing
- Rocbrutinib
- Where
- 43 sites in China
- Volunteers
- 62 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Classical Hodgkin Lymphoma, Relapsed or Refractory Classical Hodgkin Lymphoma
B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
The purpose of this study is to describe progression-free survival (PFS) in participants with relapsed or refractory classical Hodgkin lymphoma (RRHL), defined as the time from initiation of first treatment for RRHL to first…
- Trial name
- B-HOLISTIC (NCT03327571)
- Where
- South Korea
- Volunteers
- 1,770 people
- Sponsor
- Takeda
Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
This is an observational study, in which data from Taiwanese people with indolent non-Hodgkin lymphoma who will be receiving copanlisib is studied.
- Trial name
- NCT05217914
- Testing
- Copanlisib (BAY80-6946)
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Bayer
NHL, Relapsed, Adult, B-cell Lymphoma
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).
- Conditions
- NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma
- Trial name
- ANCHOR2 (NCT05487651)
- Testing
- KUR-502
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Athenex, Inc.
Diffuse Large B-Cell Lymphoma
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
The purpose of this study is to learn about the effects of three study medicines [maplirpacept (PF-07901801), tafasitamab, and lenalidomide] when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that: is…
- Trial name
- NCT05626322
- Testing
- Maplirpacept, Tafasitamab, Lenalidomide
- Where
- 7 sites in United States, Japan and 1 more
- Volunteers
- 6 people
- Sponsor
- Pfizer
Leukemia, Lymphoma
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00026351
- Testing
- rituximab, pentostatin
- Where
- 5 sites in United States
- Sponsor
- Pharmatech Oncology
Non Hodgkin Lymphoma (NHL)
NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients…
- Trial name
- POTENTIAL-M (NCT07114367)
- Testing
- NB02 (Poseltinib)
- Where
- 6 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- NOBO Medicine
Relapse/Refractory Mantle Cell Lymphoma
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
The primary objectives of this study are: Cohort 1: to provide access to brexucabtagene autoleucel (KTE-X19) for individuals with relapsed or refractory (r/r) mantle cell lymphoma (MCL) until KTE-X19 is commercially available…
- Trial name
- ZUMA-18 (NCT04162756)
- Testing
- Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
- Where
- 9 sites in United States
- Sponsor
- Kite, A Gilead Company
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049699
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
This study aims to provide a basis for further clinical development of YK012.
- Trial name
- NCT06565689
- Testing
- YK012
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Excyte Biopharma Ltd
Lymphoma, Non-Hodgkin's
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
This is a Phase III, multicenter, global, open-label, single-arm, retreatment study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with relapsed or refractory…
- Trial name
- NCT00384150
- Testing
- galiximab in combination with rituximab
- Volunteers
- 16 people
- Sponsor
- Biogen
Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL)
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Trial name
- NCT04824794
- Testing
- GEN3014, Daratumumab
- Where
- 52 sites in United States, Australia and 18 more
- Volunteers
- 130 people
- Sponsor
- Genmab
B-cell Non-Hodgkin Lymphoma
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This is a phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-cell non-Hodgkin…
- Trial name
- Lumi-NHL (NCT07123454)
- Testing
- AZD4512, Surovatamig
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 164 people
- Sponsor
- AstraZeneca
Cutaneous T-cell Lymphoma, Mycosis Fungoides
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
This study is designed to determine the recommended dose, safety, pharmacokinetics, and early efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or refractory CTCL.
- Conditions
- Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
- Trial name
- NCT01134341
- Testing
- Pralatrexate Injection, Bexarotene Capsules, Vitamin B12
- Where
- 5 sites in United States, Italy
- Volunteers
- 34 people
- Sponsor
- Acrotech Biopharma Inc.
Anaplastic Large-Cell Lymphoma
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
To investigate safety and antitumor activity of SGN-30 in patients with Hodgkin's Disease and anaplastic large cell lymphoma (ALCL).
- Trial name
- NCT00079755
- Testing
- SGN-30 (anti-CD30 mAb)
- Where
- 18 sites in United States
- Volunteers
- 80 people
- Sponsor
- Seagen Inc.
Diffuse Large B-Cell Lymphoma
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- EPCORE DLBCL-2 (NCT05578976)
- Testing
- Epcoritamab, Cyclophosphamide, Rituximab
- Where
- 331 sites in United States, Australia and 29 more
- Volunteers
- 900 people
- Sponsor
- Genmab